Mika Mustonen

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Karim Fizazi, Christophe Massard, Petri Bono et al. · The Lancet Oncology · 2014 · 194 citations · Full text

Medicine, Oncology, Urology +13

Human 17 <i>β</i>-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression

Minna Miettinen, Mika Mustonen, Matti Poutanen et al. · Biochemical Journal · 1996 · 188 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Several genes encoding ribosomal proteins are over-expressed in prostate-cancer cell lines: Confirmation of L7a and L37 over-expression in prostate-cancer tissue samples

Markku H. Vaarala, Katja Porvari, Atte P. Kyllönen et al. · International Journal of Cancer · 1998 · 110 citations

Life Sciences, Molecular Biology, Oncology +12

Human 17β-Hydroxysteroid Dehydrogenase Type 2 Messenger Ribonucleic Acid Expression and Localization in Term Placenta and in Endometrium during the Menstrual Cycle¹

Mika Mustonen, Veli Isomaa, Tommi Vaskivuo et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 84 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17

17β‐hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue

Minna Miettinen, Mika Mustonen, Matti Poutanen et al. · Breast Cancer Research and Treatment · 1999 · 63 citations

Life Sciences, Biochemistry, Molecular Biology +14